Skip to contentP
Processa Pharmaceuticals, Inc.
P
PCSAProcessa Pharmaceuticals, Inc. Q2 2017 · 10-Q
Revenue—
Net Income-$42.85K-$42.85KN/M vs Q2 2016 EPS Diluted-$0.01-$0.01N/M vs Q2 2016 Operating Income-$280,334— Operating Cash Flowderived-$74,690N/M
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Processa Pharmaceuticals, Inc. · CIK 1533743 · Engraved from SEC EDGAR
Free Cash Flowderived-$74,690— ended Jun 30, 2017 · filed Oct 4, 2017 · 96 d after period end